TMEM184C Antilichaam

TMEM184C Antibody: Anaplastic thyroid cancer is one of the most lethal forms of cancer, but the precise carcinogenic mechanism has not been identified. TMEM184C, also known as TMEM34, was identified in a cDNA microarray analysis as being down-regulated in anaplastic thyroid cancers compared to normal thyroid tissues. TMEM184C protein expression was also lower in cell lines derived from these types of cancers compared to that of normal thyroid tissues or cell lines based on other types of thyroid cancers. Furthermore, transfection of TMEM34 into KTA2 cells led to the inhibition of cell growth, suggesting that TMEM184C might act as a tumor suppressor in anaplastic thyroid cancers.

55751

Q9NVA4

NP_060711

Human, Mouse, Rat

Unconjugated

Primary Antibodies

Cancer, Cell Cycle

TMEM184C Antibody is affinity chromatography purified via peptide column.

Cat. No. 1401 - Mouse Heart Tissue Lysate

1 mg/mL

Predicted species reactivity based on immunogen sequence: Bovine: (87%)

TMEM184C Antibody is supplied in PBS containing 0.02% sodium azide.

None

Blue Ice

TMEM184C antibody can be stored at 4˚ C for three months and -20˚ C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.

IgG

TMEM184C

Transmembrane protein 184C

Homo sapiens

Akaishi J, Onda M, Okamoto J, et al. Down-regulation of an inhibitor of cell growth, transmembrane protein 34 (TMEM34), in anaplastic thyroid cancer. J. Cancer Res. Clin. Oncol.2007; 133:213-8.

TMEM184C Antibody: TMEM34, TMEM34, PRO1355, Transmembrane protein 184C, Transmembrane protein 34

ELISA, WB, IHC-P, IF

190358512

Liquid